MYC and diffuse large B-cell lymphoma: A high international prognostic index, extranodal lesions, a non‐germinal center B‐cell phenotype, BCL2 expression, the deletion of CDKN2A, and MYC rearrangements have been recognized as high‐risk features in DLBCL treated using R‐CHOP 20.